Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. We also aim to:
- Mitigate development risk and expedite regulatory timelines to product approval: We strive to reduce development risk by selecting product candidates with validated mechanisms of action.
Leverage our management team’s expertise:
Our co-founders, Dr. Clayman and Dr. Bodick, have significant capability, developed during their combined 35 years at Eli Lilly and Company, in both rapidly progressing new drugs to meaningful clinical proof of concept and in conducting successful pivotal clinical programs leading to regulatory submissions. Our executive committee includes members who are highly capable in the design and implementation of effective drug development programs. In addition, we have assembled a commercial organization with deep domain expertise in successfully launching and marketing novel pain therapies.
